New data show Novartis' Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
(Thomson Reuters ONE) -
Novartis International AG /
New data show Novartis' Gilenya® reduced brain volume loss by one third and
confirm brain volume loss link with disability in MS patients
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* New four-year data showed that continued Gilenya treatment reduced brain
volume loss by one third when compared to delaying Gilenya by two years.
* MS patients with higher rates of brain volume loss were more likely to
experience disease progression.
* Patients who remained free of disease had consistently lower rates of brain
volume loss compared to patients who experienced disease activity.
The digital press release with multimedia content can be accessed here:
Basel, October 4, 2013 - Novartis announced today new data indicating that
continued treatment with Gilenya(® )(fingolimod) led to a reduction in brain
volume loss in patients with relapsing forms of multiple sclerosis (MS), and was
associated with a higher proportion of patients remaining free of disability
progression [1],[2]. These data were presented at the ongoing 29(th) Congress of
the European Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) in Copenhagen, Denmark.
Brain volume loss is emerging as one of the best indicators of disability
progression over the long-term in MS, and is a topic of much interest within the
MS medical community[3]. Increasingly, research focus is on treatments that will
reduce the rate of brain volume loss. Gilenya is the only oral treatment for MS
that has shown early and consistent slowing of brain volume loss, and the new
data presented at ECTRIMS add to the growing evidence base of Gilenya's efficacy
in MS and reinforce the correlation between brain volume loss and disability
progression over the long-term[1].
"The data presented today are very encouraging because they are from studies
that took place over four years and show that Gilenya both reduces brain volume
loss and slows the pace of disability progression for patients with MS," said
Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals. "These
are key treatment goals for patients with this chronic and debilitating
illness."
Key findings
* Collective four-year results from the pivotal FREEDOMS and FREEDOMS
extension studies showed that patients who were treated continuously with
Gilenya 0.5 mg experienced up to one-third less brain volume loss than
patients who switched to Gilenya after receiving placebo for two years.
Thus, delay in starting treatment with Gilenya by two years was associated
with more brain volume loss[2].
* Overall, patients who remained free of disease had consistently lower rates
of brain volume loss compared to patients who experienced disease activity
and MS progression. However, the benefit of Gilenya on brain volume loss was
seen irrespective of whether patients were disease-free or had active
disease[2]. (Disease activity was evaluated by assessing measures that give
a broad evaluation of MS: disability progression, relapses and new brain
lesions detected on magnetic resonance imaging scans.)
* A separate analysis of three key studies (FREEDOMS, FREEDOMS II and
TRANFORMS) showed a correlation between disability progression and increased
brain volume loss, and this correlation increased over time[1].
* Higher baseline MRI lesion volume and baseline active lesions both predicted
subsequent loss of brain volume during the studies but patients treated with
Gilenya had less brain volume loss than those treated with placebo or IFN
beta 1a IM, irrespective of baseline lesion volume and count[4].
* MS patients with higher brain volume loss were more likely to experience
disability progression[1].
Minimizing disease progression in people with MS is a key treatment goal because
MS can have a significant impact on the quality of life for patients, families
and carers. Many patients may increasingly lose their independence due to
diminished mobility, and some may lose their ability to walk or have problems
with their sight. MS is also associated with a substantial economic burden, with
studies in several European countries reporting annual costs equivalent to
approximately ?30,000-40,000 per patient[5].
About multiple sclerosis
While its exact cause is unknown, multiple sclerosis (MS) is an autoimmune
disease of the central nervous system (CNS) that causes the body to turn against
itself by mistaking normal cells for foreign cells[6]. In MS the myelin sheath,
the covering that protects nerve fibers, is damaged by the inflammation that
occurs when the body's immune cells attack the nervous system[7]. This neuro-
inflammatory damage can occur in any area of the brain, optic nerve and spinal
cord and cause a range of physical and mental problems including loss of muscle
control and strength, vision, balance, sensation and mental function[8]. Up to
2.5 million people worldwide are affected by MS[9], most often younger people
between the ages of 20 and 40[10].
About Gilenya
Gilenya is the first oral therapy approved to treat relapsing forms of MS and
the first in a new class of compounds called sphingosine 1-phosphate receptor
modulators[11],[12]. It is thought that Gilenya works in two ways against the
destructive processes that drive MS disease progression by affecting not only
the immune system to reduce inflammatory damage but also the CNS to promote
neuroprotection and repair[12]. Gilenya is thought to act by preventing
lymphocytes (the cells that cause inflammation and damage in the CNS) from
leaving the lymphoid tissues, thus reducing their entry into the central nervous
system and potential for damage[11],[12]. Gilenya is also able to cross the
blood-brain barrier and act on the neurodegeneration process in the brain and
spinal cord[11],[12].
Gilenya is the only oral MS treatment that provides early and long-term
reduction in the rate of brain volume loss and high efficacy across all 4
disease activity measures (disability progression, relapses, MRI activity, brain
volume loss)[13]-[18]. In clinical trials, Gilenya exhibited a well-
characterized safety profile and very good tolerability profile[14],[15]. The
most common side effects were headache, hepatic enzymes increased, influenza,
sinusitis, diarrhea, back pain, and cough[14],[15]. To date, more than 71,000
patients have been treated with Gilenya demonstrating a positive benefit-risk
profile in clinical study and real-world settings[19].
Gilenya is licensed from Mitsubishi Tanabe Pharma Corporation.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by terminology such as "emerging," "will," "encouraging," "potential," or
similar expressions, or by express or implied discussions regarding potential
new indications or labeling for Gilenya or regarding potential future revenues
from Gilenya. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management regarding
future events, and involve known and unknown risks, uncertainties and other
factors that may cause actual results with Gilenya to be materially different
from any future results, performance or achievements expressed or implied by
such statements. There can be no guarantee that Gilenya will be approved for any
additional indications or labeling in any market, or at any particular time. Nor
can there be any guarantee that Gilenya will achieve any particular levels of
revenue in the future. In particular, management's expectations regarding
Gilenya could be affected by, among other things, unexpected clinical trial
results, including unexpected new clinical data and unexpected additional
analysis of existing clinical data; unexpected regulatory actions or delays or
government regulation generally; competition in general; government, industry
and general public pricing pressures; unexpected manufacturing issues; the
company's ability to obtain or maintain patent or other proprietary intellectual
property protection; the impact that the foregoing factors could have on the
values attributed to the Novartis Group's assets and liabilities as recorded in
the Group's consolidated balance sheet, and other risks and factors referred to
in Novartis AG's current Form 20-F on file with the US Securities and Exchange
Commission. Should one or more of these risks or uncertainties materialize, or
should underlying assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or expected. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2012, the Group
achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted
to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 131,000
full-time-equivalent associates and operate in more than 140 countries around
the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
References
[1] Barkhof F, Cohen JA et al. Brain volume changes, on-study correlations and
the link to disability in three fingolimod phase 3 studies. ECTRIMS 2013,
Copenhagen, Denmark.
[2] Radue E-W, de Stefano N et al. Brain atrophy and disease-free status over 4
years: analyses of the FREEDOMS core and extension trial data. ECTRIMS 2013,
Copenhagen, Denmark.
[3] Preventing brain atrophy should be the gold standard of effective therapy in
multiple sclerosis (after the first year of treatment): Commentary.
Controversies in Multiple Sclerosis. Multiple Sclerosis Journal19(8) 1007-1008.
[4] Radue E-W, Cohen J et al. Baseline predictors of brain atrophy in phase 3
studies of fingolimod. ECTRIMS 2013, Copenhagen, Denmark.
[5] Karampampa K et al. Treatment experience, burden and unmet needs (TRIBUNE)
in MS study: results from five European countries. Mult Scler. 2012 Jun;18(2
Suppl):7-15.
[6] http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed September
2013.
[7] http://www.mssociety.org.uk/what-is-ms/information-about-ms/about-ms.
Accessed September 2013.
[8] http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-
about-ms/symptoms/index.aspx. Accessed September 2013.
[9] Multiple Sclerosis International Federation. Atlas of MS [online]. Available
at: www.atlasofms.org. Accessed September 2013.
[10] http://emsp.org/multiple-sclerosis/ms-fact-sheet. Accessed September 2013.
[11] Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects
in the immune and the central nervous system. Br J Pharmacol
2009;158(5):1173-1182.
[12] Chun J, Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in
Multiple Sclerosis. Clin Neuropharmacol. 2010 March-April;33(2):91-101.
[13] Chin PS, Calabresi PA, Zhang Y, von Rosenstiel P, Kappos L. Early effect of
fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis.
Poster presented at: 28th Congress of the European Committee for Treatment and
Research in Multiple Sclerosis; October 10-13, 2012; Lyon, France. Abstract
P459.
[14] Kappos L, Radue E-W, O'Connor P, et al; for FREEDOMS Study Group. A
placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N
Engl J Med. 2010;362(5):387-401.
[15] Cohen JA, Barkhof F, Comi G, et al; for TRANSFORMS Study Group. Oral
fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl
J Med. 2010;362(5):402-415.
[16] Cohen J, et al. Fingolimod-effect on brain atrophy and clinical/MRI
correlations in Three Phase 3 studies - TRANSFORMS, FREEDOMS and FREEDOMS II.
Abstract presented at AAN, San Diego, March 2013.
[17] Montalban X, Barkhof F, Comi G, et al. Long-term comparison of fingolimod
with interferon beta-1a: results of 4.5-year follow-up from the extension phase
III TRANSFORMS study Poster presented at: 28th Congress of the European
Committee for Treatment and Research in Multiple Sclerosis; October
10-13, 2012; Lyon, France. Abstract P517.
[18] Kappos L, Radue E-W, O'Connor P, et al. Phase 3 FREEDOMS study extension:
fingolimod (FTY720) efficacy in patients with relapsing-remitting multiple
sclerosis receiving continuous or placebo-fingolimod switched therapy for up to
4 years. Poster presented at: 28th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis; October 10-13, 2012: Lyon, France.
Poster P979.
[19] Novartis data on file.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Katrina Lucking
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 12 18 (direct)
+41 79 593 4202 (mobile) +41 79 171 8267 (mobile)
eric.althoff(at)novartis.com katrina.lucking(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301
Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1733406/580392.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1733406]
Unternehmensinformation / Kurzprofil:
Datum: 04.10.2013 - 07:16 Uhr
Sprache: Deutsch
News-ID 302854
Anzahl Zeichen: 16761
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 303 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New data show Novartis' Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
